TNFRSF17 and plasma cell myeloma: For example, the BiTE®-based antibody BI-836909 (AMG 420), which exhibited good efficacy and potency in preclinical studies by causing depletion of BCMA-positive myeloma cells [206], is now the subject of a phase I dose-escalation study as monotherapy in RRMM patients (NCT02514239) (https://ash.confex.com/ash/2018/webprogram/Paper109769.html (accessed on 17 November 2018)).